![9-[(2R,3S,5S)-3-Fluoro-5-(Hydroxymethyl)Oxolan-2-Yl]-3H-Purin-6-One](https://static.cymitquimica.com/products/3D/img/FF98319.png "Haga clic para ampliar")
9-[(2R,3S,5S)-3-Fluoro-5-(Hydroxymethyl)Oxolan-2-Yl]-3H-Purin-6-One
CAS: 117525-25-4
Ref. 3D-FF98319
| Tamaño no definido | A consultar |
Información del producto
- 2'-F-dd-Aral
- 6H-Purin-6-one, 9-(2,3-dideoxy-2-fluoro-beta-D-threo-pentofuranosyl)-1,9-dihydro-
- 9-(2,3-dideoxy-2-fluoro-beta-D-threo-pentofuranosyl)-3,9-dihydro-6H-purin-6-one
9-[(2R,3S,5S)-3-Fluoro-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one (FHA) is a prodrug that contains a hydroxymethyl group. FHA can be hydrolyzed by the enzyme aldehyde oxidase to form 9-[(2R,3S,5S)-3-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one (FAU). FAU is more potent than FHA and has been shown to inhibit HIV replication in cell culture. FHA was administered to humans and its pharmacokinetic properties were studied. The plasma concentration of FHA increased with time after administration and reached a maximum level at about 3 hours. The maximum concentration of FAU was found at about 1 hour. The elimination half life of both compounds was approximately 2 hours. The workstation architecture used
Propiedades químicas
Consulta técnica sobre: 3D-FF98319 9-[(2R,3S,5S)-3-Fluoro-5-(Hydroxymethyl)Oxolan-2-Yl]-3H-Purin-6-One
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.
